Latest Close
₹2,515.10
+1.73%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹2,804.65
200 DMA
₹2,510.77
1 year gain / loss
−₹106.60(-4.07%)
₹2,621.70 → ₹2,515.10· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Market Cap
₹42,072.84 Cr
P/E
39.39×
Sector -38.72× · above
P/B
18.56×
Sector 4.11× · above
EV / EBITDA
26.91×
Sector 19.14× · above
ROE
45.69%
Sector 0.37%
ROCE
61.23%
Sector 6.55%
ROA
24.70%
Sector -17.04%
Cash Flow / Profit
0.87×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 982.2 -4.8% | 322.45 | 237.18 -14.6% |
| Mar 2026 | 1,031.25 -3.9% | 373.1 | 277.86 -6.0% |
| Dec 2025 | 1,073.38 +5.9% | 399.93 | 295.62 +14.8% |
| Sep 2025 | 1,013.51 | 354 | 257.49 |
Dividend
29 May 2026 · ₹57